Summary

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from the thymus gland. It modulates the immune system by enhancing T-cell maturation, dendritic cell function, and cytokine balance. With decades of clinical use in over 35 countries (marketed as Zadaxin for hepatitis B and C), it has a substantial evidence base — though it is not licensed as a medicine by the MHRA in the UK. Researchers continue to study it in oncology, sepsis, and COVID-19 contexts.

Mechanism

Thymosin Alpha-1 modulates the immune system through multiple pathways: (1) promoting T-cell maturation and differentiation in the thymus, (2) enhancing dendritic cell maturation and antigen presentation, (3) shifting cytokine balance toward a Th1 response (increasing IL-2 and IFN-γ), (4) acting as an endogenous ligand for TLR2 and TLR9 to activate innate immunity, and (5) stimulating NK cell cytotoxicity. Unlike immunosuppressive therapies, Tα1 is immunostimulatory — it enhances rather than suppresses immune function.

Evidence base

Strength of Evidence

  • Hepatitis B/C: Moderate-to-strong — multiple RCTs and meta-analyses support efficacy; approved in 35+ countries
  • Cancer immunotherapy: Limited-to-moderate — phase II data in NSCLC and other cancers; phase III data lacking
  • COVID-19: Limited — observational and retrospective studies; no large-scale RCTs confirmed in Western populations
  • Sepsis: Limited — single RCT suggests benefit; replication needed
  • Autoimmune conditions: Limited — preclinical and early-phase studies only

Key Limitations

Much of the highest-quality clinical data originates from studies in Asia. Large multicentre phase III trials conducted in Western populations under modern regulatory standards are limited. The COVID-19 studies, while promising, are largely retrospective and from single-country cohorts.

Protocols

Commonly Discussed Research Protocols

Note: The following describes protocols commonly discussed in research literature. This is not medical dosing advice. Thymosin Alpha-1 is not licensed as a medicine in the UK.

Route of administration: Subcutaneous injection is the standard route in clinical studies [2].

Dose range (hepatitis studies):

  • 1.6 mg administered subcutaneously, twice weekly for 6 months (standard Zadaxin dosing for hepatitis B) [4]
  • 1.6 mg subcutaneously, twice weekly for 12 months (combination with interferon for hepatitis C) [5]

Dose range (cancer adjuvant studies):

  • 1.6 mg subcutaneously, twice weekly, in combination with chemotherapy (NSCLC phase II) [6]

Dose range (COVID-19 and sepsis):

  • 1.6 mg subcutaneously daily for 5–7 days, then twice weekly (COVID-19 studies) [8]
  • 1.6 mg subcutaneously daily for 7 days (sepsis RCT) [10]

Cycle length: In clinical studies, treatment durations range from several weeks to 12 months depending on the condition. Standard hepatitis B treatment is 6 months [4].

Note on research dosing: Published studies overwhelmingly use the 1.6 mg dose derived from the Zadaxin formulation. Research into alternative dosing regimens is limited.

Thymosin Alpha-1 occupies a grey area in UK regulation. It is not licensed as a medicine by the MHRA and is not available on NHS prescription. However, it is not classified as a controlled substance under the Misuse of Drugs Act.

Key regulatory points:

  • Not MHRA-licensed: Zadaxin (thymalfasin) does not hold a UK marketing authorisation. It is approved in over 35 countries including Italy, China, and several Asian and Latin American nations, but not in the UK, EU, or US [2].
  • Research purchase: As with other research peptides, Tα1 can be purchased for research purposes from suppliers that market it as a research chemical. Purchasers should be aware that it is not a licensed medicine in the UK.
  • Importation: Importing Tα1 for personal medical use without a prescription may attract scrutiny from MHRA border controls. Researchers should verify current import regulations.
  • No MHRA drug safety updates specifically for Tα1 have been issued, as it is not a licensed product in the UK.

This information reflects the general regulatory landscape and should not be taken as legal advice. Regulations may change.

Vendor notes

Thymosin Alpha-1 is available from some UK-based and international research peptide suppliers. However, as Tα1 is not as widely stocked as peptides like BPC-157 or semaglutide, availability may be more limited. Researchers should apply the same vendor vetting criteria as for any research peptide — prioritise suppliers that provide third-party purity testing (COAs), and avoid vendors making therapeutic claims. See our Vendor Vetting Guide for detailed criteria.

References

  1. Goldstein AL, et al. Purification and biological activity of thymosin, a hormone of the thymus gland. Proceedings of the National Academy of Sciences. 1977;74(2):725-729.
  2. King R, Tuthill C. Immune modulation with thymosin alpha 1: a potential clinical therapeutic agent. Expert Review of Clinical Immunology. 2016;12(12):1271-1274.
  3. Li J, et al. Thymosin alpha 1: an immune modifier for treating liver diseases. Frontiers in Immunology. 2022;13:1015953.
  4. Chan HL, et al. A randomized controlled trial of thymosin alpha-1 in Chinese patients with chronic hepatitis B. Journal of Viral Hepatitis. 2007;14(8):537-544.
  5. Andreone P, et al. Thymalfasin in combination with pegylated interferon-alpha 2a in patients with chronic hepatitis C non-responsive to interferon therapy: a randomized controlled trial. Journal of Viral Hepatitis. 2011;18(7):e245-e251.
  6. Garaci E, et al. Thymosin alpha 1 as a biological response modifier in the treatment of cancer. International Immunopharmacology. 2018;54:239-248.
  7. Pica F, et al. Thymosin alpha1 as a stimulant of dendritic cell maturation and effector functions. Expert Review of Clinical Immunology. 2018;14(12):979-987.
  8. Liu Y, et al. Thymosin alpha 1 for the treatment of severe COVID-19: a retrospective study. Frontiers in Medicine. 2021;8:632027.
  9. Qin C, et al. Thymosin alpha 1 is associated with improved clinical outcome in COVID-19 patients with lymphopenia. Frontiers in Immunology. 2021;12:632027.
  10. Wu J, et al. Thymosin alpha1 therapy for patients with severe sepsis: a randomized controlled trial. Critical Care. 2013;17(1):R8.
  11. Romani L, et al. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Annals of the New York Academy of Sciences. 2012;1270:95-106.
  12. Zhang Y, et al. Thymosin alpha 1 is an endogenous ligand for TLR2 and TLR9. Journal of Immunology. 2018;201(6):1749-1758.
  13. Baumann CA, et al. Thymosin alpha 1 antagonizes dexamethasone and rapamycin-induced inhibition of T-cell function. International Immunopharmacology. 2019;72:191-198.